Calpain

Subscribe to Selected New Research on Calpain

1026 relevant articles (26 outcomes, 139 trials/studies) found for this Bio-Agent

Description: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.

Also Known As:

Ca2+-Activated Protease; Calcium-Activated Neutral Proteinase; Calcium-Activated Protease; Calcium-Dependent Neutral Protease; Calpain I; Calpain II; Desminase; Ca2+ Activated Protease; Calcium Activated Neutral Protease; Calcium Activated Neutral Proteinase; Calcium Activated Protease; Calcium Dependent Neutral Protease; Calcium Dependent Neutral Proteinase; I, Calpain; II, Calpain; Neutral Protease, Calcium-Activated; Neutral Protease, Calcium-Dependent; Neutral Proteinase, Calcium-Activated; Neutral Proteinase, Calcium-Dependent; Protease, Ca2+-Activated; Protease, Calcium-Activated; Protease, Calcium-Activated Neutral; Protease, Calcium-Dependent Neutral; Proteinase, Calcium-Activated Neutral; Proteinase, Calcium-Dependent Neutral; Calcium-Activated Neutral Protease; Calcium-Dependent Neutral Proteinase

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ray, Swapan K: 15 articles (06/2008 - 06/2002)
2.	Banik, Naren L: 14 articles (06/2008 - 06/2002)
3.	Banik, N L: 9 articles (06/2004 - 01/2000)
4.	Sribnick, Eric A: 5 articles (05/2008 - 07/2003)
5.	Wang, Kevin K W: 5 articles (03/2007 - 12/2005)
6.	Hayes, Ronald L: 5 articles (03/2007 - 01/2004)
7.	Azuma, Mitsuyoshi: 5 articles (05/2006 - 02/2002)
8.	Shearer, Thomas R: 5 articles (05/2006 - 02/2002)
9.	Ray, S K: 5 articles (06/2004 - 06/2000)
10.	Wilford, G G: 5 articles (06/2004 - 06/2000)

Related Diseases

1.	Ischemia 04/01/2007 - "Our study further indicates that accumulation of p35 and its calpain-mediated cleavage product, p25 may account for the deregulation of Cdk5 induced by transient ischemia. " 12/01/2003 - "In the present study, we investigated the activity and expression of CaN and the effect of calpain in rat heart after ischemia and reperfusion. " 07/01/2001 - "This study examined the temporal and spatial characteristics of brain calpain activity after transient forebrain ischemia (TFI) in rats. " 04/20/1998 - "This study provides the first demonstration of a close and early temporal relationship between calpain proteolysis, subcellular damage to the pyramidal cells and their loss of function following global ischemia, prior to their eventual death." 02/01/1997 - "The current study is designed to generate direct support for the theory that both ischemia and partial outlet obstruction result in the activation of calpain. " Order ALL the reference details at left...
2.	Cataract (Cataracts) 03/01/2008 - "The ovine hereditary cataract is a useful nonrodent model to study the role of calpain proteolysis in cataract formation." 06/01/2007 - "CONCLUSIONS: The present study shows for the first time that calpain 3 is necessary for the formation of age-dependent nuclear cataracts in alpha3Cx46-/- mice. " 06/01/2004 - "OBJECTIVE: To study the role of calpain in the mechanism of oxidative cataract through detecting the level of intracellular free Ca(2+), the expression and proteolytic activity of calpain in the lens epithelial cells (LECs) of H(2)O(2)-induced cataract. " 09/11/2008 - "When Ca(2+) homeostasis is disrupted, calpain overactivation causes unregulated proteolysis, which can contribute to diseases such as postischemic injury and cataract formation. " 06/14/2007 - "The most water soluble triazene 17a (IC50 of 90 nM) retards calpain-induced cataract formation in lens culture." Order ALL the reference details at left...
3.	Necrosis 08/01/2009 - "Calpain-produced alphaII-SBDPs (150 kDa+145 kDa bands-necrosis) 8 hours after HCA were significantly increased (p = 0.02) as compared with levels before HCA, and remained elevated at 24 hours after HCA. " 01/01/2006 - "When compared to rats administered LPS alone, administration of calpain 1 inhibitor prior to LPS significantly reduced hepatic iNOS expression, hepatic neutrophil infiltration and attenuated midzonal hepatic necrosis. " 11/01/2005 - "Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis." 02/01/2005 - "The CA1 subfield shifted from apoptosis-related neuronal death at P5 and P9 to necrosis-related calpain activation at P21 and P60. " 02/01/2005 - "Necrosis-related calpain activation was similar at all ages. " Order ALL the reference details at left...
4.	Myocardial Infarction 05/01/1989 - "We examined the efficacy of the combination of coronary reperfusion and calcium-activated neutral protease (CANP) inhibitor (E-64c) for the treatment of acute myocardial infarction in dogs. " 10/18/2002 - "This study investigated the contribution of cardiac L- and T-type Ca(2+) channels in the calpain-mediated myocardial damage following myocardial infarction. " 02/01/2001 - "The aim of this study was to investigate the contribution of AT(1) and AT(2) receptors in the regulation of calpain-mediated myocardial damage following myocardial infarction (MI). " 11/01/2009 - "Calpain inhibition preserves myocardial structure and function following myocardial infarction." 02/01/2005 - "CONCLUSION: These results suggest that attenuation in calpain-induced degradation of DRP complex is a possible mechanism for the Tra- or Can-mediated improvement of the pathogenesis of CHF following myocardial infarction." Order ALL the reference details at left...
5.	Parkinsonian Disorders (Parkinsonism) 10/01/2008 - "A key focus of our study is the role that calpain, a Ca(2+)-activated neutral protease, plays in disrupting the structural-functional integrity of the spinal cord in the context of spinal cord degeneration in experimental parkinsonism. " 06/01/2008 - "The key focus of this review is to discuss the role that calpain plays in disrupting the structural and functional integrity of the spinal cord in these experimental models of parkinsonism. " 08/01/2006 - "Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism." 08/01/2006 - "Hence, we examined the neuroprotective efficacy of calpeptin, a specific inhibitor of calpain, in cell culture model of experimental parkinsonism." 06/01/2008 - "In this review, we summarize the evidence in support of involvement of calpain, a Ca(2+)-activated non-lysosomal protease, in spinal cord degeneration in two models of experimental parkinsonism induced by the neurotoxin 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine and also the environmental toxin rotenone. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	calpain inhibitors
2.	Calcium
3.	Cysteine Endopeptidases (Cysteine Proteases)
4.	calpeptin
5.	Caspase 3 (Caspase-3)
6.	Proteins (Proteins, Gene)
7.	NF-kappa B (NF-kB)
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Glucose (Dextrose)
10.	calpain inhibitor III

Related Therapies and Procedures

1.	Lenses
2.	Protein-Restricted Diet (Diet, Protein Restricted)
3.	Ligation
4.	Drug Therapy (Chemotherapy)
5.	Warm Ischemia

Best Treatments:
Research Summary Report
on Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2883 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>